# Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

> **NCT06479720** · PHASE4 · RECRUITING · sponsor: **Mackay Memorial Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Effect of Drug
- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Combined pharmacotherapy with Solifenacin and Mirabegron
- **DRUG:** Solifenacin with vaginal estrogen cream
- **DRUG:** Mirabegron with vaginal estrogen cream

## Key facts

- **NCT ID:** NCT06479720
- **Lead sponsor:** Mackay Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479720, "Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06479720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*